Viewing Study NCT05336812


Ignite Creation Date: 2025-12-26 @ 10:43 PM
Ignite Modification Date: 2026-03-02 @ 4:06 AM
Study NCT ID: NCT05336812
Status: RECRUITING
Last Update Posted: 2025-06-03
First Post: 2022-03-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Sponsor: Ohio State University Comprehensive Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module